ArticleFrontiers in microbiology2018
Article in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.Current research in microbial sciences · 2025Review
- Calcineurin activity in Fonsecaea pedrosoi: tacrolimus and cyclosporine A inhibited conidia growth, filamentation and showed synergism with itraconazole.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Chromoblastomycosis in French Guiana: Epidemiology and Practices, 1955-2023.Journal of fungi (Basel, Switzerland) · 2024Article
- Silver(I) 1,10-Phenanthroline Complexes Are Active againstJournal of fungi (Basel, Switzerland) · 2023Article
- Liposomal Delivery of Saquinavir to Macrophages Overcomes Cathepsin Blockade byInternational journal of molecular sciences · 2023Article
- Biofilm Formation by Chromoblastomycosis FungiJournal of fungi (Basel, Switzerland) · 2022Article
- Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned fromJournal of fungi (Basel, Switzerland) · 2021Article
- Reviewing the Etiologic Agents, Microbe-Host Relationship, Immune Response, Diagnosis, and Treatment in Chromoblastomycosis.Journal of immunology research · 2021Review
- Repurposing Saquinavir for Host-Directed Therapy to Control Mycobacterium Tuberculosis Infection.Frontiers in immunology · 2021Article
- Aspartic peptidase ofJournal of enzyme inhibition and medicinal chemistry · 2020Article
- Genomics and Virulence ofFrontiers in genetics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.